Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525

Central Nervous System TumorsRadio-Oncology

Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status

Radiother Oncol.

Wee CW, Kim E, Kim N, Kim IA, Kim TM, Kim YJ, Park CK, Kim JW, Kim CY, Choi SH, Kim JH, Park SH, Choe G, Lee ST, Chang JH, Kim SH, Suh CO, Kim IH

doi: 10.1016/j.radonc.2017.02.014.

Skin Cancer

Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology

Int J Mol Sci.

Krebs FS, Gérard C, Wicky A, Aedo-Lopez V, Missiaglia E, Bisig B, Trimech M, Michielin O, Homicsko K, Zoete V

doi: 10.3390/ijms21218021.

Central Nervous System TumorsRadio-Oncology

MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Review

Neuro Oncol

Brandner S, McAleenan A, Kelly C, Spiga F, Cheng HY, Dawson S, Schmidt L, Faulkner CL, Christopher W, Jefferies S, Higgins JPT, Kurian KM

doi: 10.1093/neuonc/noab105

Lung Cancer

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.

Central Nervous System Tumors

Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma

J Clin Oncol.

Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL, Timmers CD, Becker AP, Salavaggione AL, Liu Z, Aldape K, Brachman DG, Gertler SZ, Murtha AD, Schultz CJ, Johnson D, Laack NN, Hunter GK, Crocker IR, Won M, Chakravarti A

doi: 10.1200/JCO.19.02983.

Further Publications

Precision Oncology and Gender Medicine – Moving Forward, Slowly but Surely

healthbook TIMES Oncology Hematology

1Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), CH-1011, Switzerland 2International Cancer Prevention Institute, Epalinges, CH-1066, Switzerland *corresponding authors

Multilayered omics-based analysis of a head and neck cancer model of cisplatin resistance reveals intratumoral heterogeneity and treatment-induced clonal selection

Clin Cancer Res.

Niehr F, Eder T, Pilz T, Konschak R, Treue D, Klauschen F, Bockmayr M, Türkmen S, Jöhrens K, Budach V, Tinhofer I

doi: 10.1158/

Breast Cancer

Breast Cancer Treatment in the Era of Precision Medicine

1Breast Cancer Center, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland

Central Nervous System TumorsBreast CancerGastrointestinal CancerGynecologic CancerHead and Neck CancerRadio-Oncology

A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study

Lancet Oncol.

Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB, Torres-Roca JF

doi: 10.1016/

Related content